FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161859941> ?p ?o ?g. }

• W2161859941 endingPage "2545" @default.
• W2161859941 startingPage "2537" @default.
• W2161859941 abstract "ABSTRACT A lack of patient response to alpha interferon (α-IFN) plus ribavirin (RBV) treatment is a major problem in eliminating hepatitis C virus (HCV). We screened chemical libraries for compounds that enhanced cellular responses to α-IFN and identified a triterpenoid, toosendanin (TSN). Here, we studied the effects and mechanisms of action of TSN on HCV replication and its effect on α-IFN signaling. We treated HCV genotype 1b replicon-expressing cells and HCV-J6/JFH-infected cells with TSN, with or without α-IFN, and the level of HCV replication was quantified. To study the effects of TSN on α-IFN signaling, we detected components of the interferon-stimulated gene factor 3 (ISGF3), phosphorylated signal transducer and activator of transcription 1 (STAT1), and STAT2 by Western blotting analysis; expression levels of mRNA of interferon regulatory factor 9 using real-time reverse transcription-PCR (RT-PCR); and interferon-stimulated response element reporter activity and measured the expression levels of interferon-inducible genes for 2′,5′-oligoadenylate synthetase, MxA, protein kinase R, and p56 using real-time RT-PCR. TSN alone specifically inhibited expression of the HCV replicon (50% effective concentration = 20.6 nM, 50% cytotoxic concentration > 3 μM, selectivity index > 146). Pretreatment with TSN prior to α-IFN treatment was more effective in suppressing HCV replication than treatment with either drug alone. Although TSN alone did not activate the α-IFN pathway, it significantly enhanced the α-IFN-induced increase of phosphorylated STATs, interferon-stimulated response element activation, and interferon-stimulated gene expression. TSN significantly increased baseline expression of interferon regulatory factor 9, a component of interferon-stimulated gene factor 3. Antiviral effects of treatment with α-IFN can be enhanced by pretreatment with TSN. Its mechanisms of action could potentially be important to identify novel molecular targets to treat HCV infection." @default.
• W2161859941 created "2016-06-24" @default.
• W2161859941 creator A5006576557 @default.
• W2161859941 creator A5011131626 @default.
• W2161859941 creator A5012385062 @default.
• W2161859941 creator A5024713150 @default.
• W2161859941 creator A5031307021 @default.
• W2161859941 creator A5034660747 @default.
• W2161859941 creator A5034909949 @default.
• W2161859941 creator A5038887844 @default.
• W2161859941 creator A5045376146 @default.
• W2161859941 creator A5054571606 @default.
• W2161859941 creator A5055214556 @default.
• W2161859941 creator A5063108279 @default.
• W2161859941 creator A5074620650 @default.
• W2161859941 creator A5077151069 @default.
• W2161859941 creator A5087212930 @default.
• W2161859941 creator A5088814392 @default.
• W2161859941 date "2011-06-01" @default.
• W2161859941 modified "2023-10-01" @default.
• W2161859941 title "Inhibitory Effect of a Triterpenoid Compound, with or without Alpha Interferon, on Hepatitis C Virus Infection" @default.
• W2161859941 cites W1973151016 @default.
• W2161859941 cites W1983585526 @default.
• W2161859941 cites W1983805610 @default.
• W2161859941 cites W1987417745 @default.
• W2161859941 cites W1988224601 @default.
• W2161859941 cites W1991001144 @default.
• W2161859941 cites W1991637406 @default.
• W2161859941 cites W1997076006 @default.
• W2161859941 cites W2003579943 @default.
• W2161859941 cites W2004323635 @default.
• W2161859941 cites W2018637841 @default.
• W2161859941 cites W2019523835 @default.
• W2161859941 cites W2027545702 @default.
• W2161859941 cites W2031913105 @default.
• W2161859941 cites W2033880955 @default.
• W2161859941 cites W2044193462 @default.
• W2161859941 cites W2046309921 @default.
• W2161859941 cites W2049148552 @default.
• W2161859941 cites W2058863196 @default.
• W2161859941 cites W2059382566 @default.
• W2161859941 cites W2059638323 @default.
• W2161859941 cites W2063285149 @default.
• W2161859941 cites W2066352633 @default.
• W2161859941 cites W2074134575 @default.
• W2161859941 cites W2078464693 @default.
• W2161859941 cites W2084447898 @default.
• W2161859941 cites W2086414517 @default.
• W2161859941 cites W2090342481 @default.
• W2161859941 cites W2091554591 @default.
• W2161859941 cites W2096372976 @default.
• W2161859941 cites W2108399976 @default.
• W2161859941 cites W2112876622 @default.
• W2161859941 cites W2122973751 @default.
• W2161859941 cites W2126325568 @default.
• W2161859941 cites W2133003425 @default.
• W2161859941 cites W2135330520 @default.
• W2161859941 cites W2139405922 @default.
• W2161859941 cites W2143671051 @default.
• W2161859941 cites W2147126871 @default.
• W2161859941 cites W2151437059 @default.
• W2161859941 cites W2160063406 @default.
• W2161859941 cites W2161504997 @default.
• W2161859941 cites W2167559643 @default.
• W2161859941 cites W2332630894 @default.
• W2161859941 cites W2470223656 @default.
• W2161859941 doi "https://doi.org/10.1128/aac.01780-10" @default.
• W2161859941 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3101404" @default.
• W2161859941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21444704" @default.
• W2161859941 hasPublicationYear "2011" @default.
• W2161859941 type Work @default.
• W2161859941 sameAs 2161859941 @default.
• W2161859941 citedByCount "16" @default.
• W2161859941 countsByYear W21618599412012 @default.
• W2161859941 countsByYear W21618599412013 @default.
• W2161859941 countsByYear W21618599412016 @default.
• W2161859941 countsByYear W21618599412017 @default.
• W2161859941 countsByYear W21618599412019 @default.
• W2161859941 countsByYear W21618599412020 @default.
• W2161859941 countsByYear W21618599412021 @default.
• W2161859941 countsByYear W21618599412022 @default.
• W2161859941 countsByYear W21618599412023 @default.
• W2161859941 crossrefType "journal-article" @default.
• W2161859941 hasAuthorship W2161859941A5006576557 @default.
• W2161859941 hasAuthorship W2161859941A5011131626 @default.
• W2161859941 hasAuthorship W2161859941A5012385062 @default.
• W2161859941 hasAuthorship W2161859941A5024713150 @default.
• W2161859941 hasAuthorship W2161859941A5031307021 @default.
• W2161859941 hasAuthorship W2161859941A5034660747 @default.
• W2161859941 hasAuthorship W2161859941A5034909949 @default.
• W2161859941 hasAuthorship W2161859941A5038887844 @default.
• W2161859941 hasAuthorship W2161859941A5045376146 @default.
• W2161859941 hasAuthorship W2161859941A5054571606 @default.
• W2161859941 hasAuthorship W2161859941A5055214556 @default.
• W2161859941 hasAuthorship W2161859941A5063108279 @default.
• W2161859941 hasAuthorship W2161859941A5074620650 @default.
• W2161859941 hasAuthorship W2161859941A5077151069 @default.
• W2161859941 hasAuthorship W2161859941A5087212930 @default.

• next